Sun Pharma Bought The Wreck. Twice.

Описание: In 2014 Sun Pharma paid $3.2 billion for Ranbaxy, a company whose American arm had just pleaded guilty to seven felony counts and paid a $500 million fine. Twelve years later, it agreed to buy Organon for $11.75 billion. This is the story of both deals — and the one clause that made the first one work.

0:00 The cold open — seven felonies
0:45 The tube of Volini in your house
1:26 June 2008: Daiichi buys in
1:50 Six months to a write-off
3:03 Four of five plants banned
3:56 Everybody sees the same wreck
4:10 April 2014: Sun buys the wreck
4:49 The 63.5% clause nobody reported
5:23 What Sun was actually buying
6:26 Daiichi's exit
7:00 The richest man in India
7:43 April 2026: Organon, $11.75 billion
8:38 Nine and a half billion of borrowed money
9:09 Where the stock stands
9:50 Who is holding it

Sources: US Department of Justice press release, 13 May 2013; Sun Pharmaceutical Industries press release, April 2014; Daiichi Sankyo earnings report via Fierce Pharma; Organon press release, 26 April 2026; Business Standard; Reuters; C&EN.

Not investment advice. Share prices and market data are accurate as of the upload date. The Organon acquisition had not closed at the time of publication.

#SunPharma #Ranbaxy #IndianPharma #IndianStockMarket #BusinessHistory #Organon #Nifty50